Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Consensus Price Target from Brokerages

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have earned an average recommendation of “Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $36.60.

KNSA has been the topic of a number of research analyst reports. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Evercore ISI lifted their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th.

Insider Activity

In related news, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This trade represents a 13.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,092 shares of company stock worth $673,039. Insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of KNSA. Franklin Resources Inc. raised its position in Kiniksa Pharmaceuticals by 1.7% during the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock valued at $1,798,000 after buying an additional 1,100 shares during the period. XTX Topco Ltd increased its holdings in shares of Kiniksa Pharmaceuticals by 62.2% in the 3rd quarter. XTX Topco Ltd now owns 27,302 shares of the company’s stock valued at $682,000 after purchasing an additional 10,474 shares during the period. Castleark Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at about $4,178,000. Jane Street Group LLC lifted its position in shares of Kiniksa Pharmaceuticals by 1,064.4% in the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock worth $8,624,000 after purchasing an additional 315,456 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $1,192,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ:KNSA opened at $19.94 on Friday. The company’s 50-day moving average price is $22.52 and its 200 day moving average price is $23.16. The company has a market cap of $1.44 billion, a PE ratio of -142.42 and a beta of 0.27. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same period last year, the firm posted ($0.20) EPS. The business’s quarterly revenue was up 67.4% on a year-over-year basis. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.